GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » 3-Year FCF Growth Rate

Santhera Pharmaceuticals Holding AG (XSWX:SANN) 3-Year FCF Growth Rate : 0.00% (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG 3-Year FCF Growth Rate?

Santhera Pharmaceuticals Holding AG's Free Cash Flow per Share for the six months ended in Jun. 2023 was CHF-1.38.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 49.80% per year. The lowest was -69.90% per year. And the median was 20.45% per year.


Competitive Comparison of Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate falls into.



Santhera Pharmaceuticals Holding AG 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Santhera Pharmaceuticals Holding AG  (XSWX:SANN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Santhera Pharmaceuticals Holding AG 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Traded in Other Exchanges
Address
Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines